---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-039694"
form_type: "8-K"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T17:55:55.966977+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aditxt subsidiary Adimune reports positive preclinical data for ADI-100; clinical trials planned in Germany and US

## Summary
- Completed toxicology, bio-distribution, persistence, and antibody formation studies for ADI-100 with no safety flags.
- Ex vivo data from human patient cells showed ADI-100 down-regulates anti-GAD immune activity, supporting clinical advancement.
- IP portfolio includes 130-150 patents/applications protecting the ADI platform as a tolerance delivery system.
- Clinical studies planned: psoriasis and type 1 diabetes in Germany; stiff-person syndrome and neurological in US.
- ADI-100 aims to restore immune tolerance using apoptotic cells and modified antigen (GAD), not general immune suppression.

## SEC filing metadata
- accession: 0001213900-25-039694
- form_type: 8-K
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390025039694/0001213900-25-039694-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390025039694/ea0240881-8k_aditxt.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-039694
- JSON: https://secwatch.observer/filing/0001213900-25-039694.json
- Plain text: https://secwatch.observer/filing/0001213900-25-039694.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.